Efficacy and Safety of Seralutinib in the Treatment of Adults With Pulmonary Arterial Hypertension
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Respiratory Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial
Lancet Respir Med 2024 May 02;[EPub Ahead of Print], RP Frantz, VV McLaughlin, S Sahay, P Escribano Subías, RL Zolty, RL Benza, RN Channick, KM Chin, AR Hemnes, LS Howard, O Sitbon, JL Vachiéry, RT Zamanian, M Cravets, RF Roscigno, D Mottola, R Osterhout, JM Bruey, E Elman, CA Tompkins, E Parsley, R Aranda, LS Zisman, HA GhofraniFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.